Baylor University Medical Center, Dallas, TX, USA. Texas A & M College of Medicine, Dallas, TX, USA.
Am J Gastroenterol. 2018 May;113(5):660-669. doi: 10.1038/s41395-018-0032-9. Epub 2018 May 1.
Chronic diarrhea is a common clinical problem, affecting roughly 5% of the population in any given year. Evaluation and management of these patients can be difficult due to the extensive differential diagnosis of this symptom. Many patients with chronic diarrhea have structural problems, such as inflammatory bowel disease or celiac disease, that can be readily identified. Others do not, and often are given a diagnosis of irritable bowel syndrome with diarrhea (IBS-D). When based on generally accepted clinical criteria, a diagnosis of IBS-D identifies a group of patients who are unlikely to have disorders producing anatomical changes in the gut. It is less clear that a diagnosis of IBS-D identifies a specific pathophysiology or leads to better management of symptoms. Disorders such as small intestinal bacterial overgrowth, bile acid malabsorption, food intolerance, and motility disorders may account for symptoms in patients with IBS-D. More effective tests are being developed to identify the clinical problems underlying IBS-D and may lead to more specific diagnoses that may improve the results of therapy. Application of the principles of precision medicine (identifying a specific mechanism for disease and applying treatments that work on that mechanism) should lead to more expeditious diagnosis and treatment for patients with chronic diarrhea including IBS-D, but currently is limited by the availability of sufficiently sensitive and specific tests for underlying mechanisms that can predict response to treatment.
慢性腹泻是一种常见的临床问题,大约影响每年 5%的人口。由于这种症状的广泛鉴别诊断,这些患者的评估和管理可能很困难。许多慢性腹泻患者存在结构问题,如炎症性肠病或乳糜泻,这些问题很容易识别。其他患者则没有,通常被诊断为腹泻型肠易激综合征(IBS-D)。当基于普遍接受的临床标准时,IBS-D 的诊断确定了一组不太可能患有导致肠道解剖结构变化的疾病的患者。尚不清楚 IBS-D 的诊断是否确定了特定的病理生理学或导致更好的症状管理。小肠细菌过度生长、胆汁酸吸收不良、食物不耐受和运动障碍等疾病可能是 IBS-D 患者症状的原因。正在开发更有效的测试来识别 IBS-D 背后的临床问题,这可能会导致更具体的诊断,从而改善治疗效果。精准医学(确定疾病的特定机制并应用针对该机制的治疗方法)的应用原则应该会为包括 IBS-D 在内的慢性腹泻患者带来更迅速的诊断和治疗,但目前受到能够预测治疗反应的潜在机制的足够敏感和特异性测试的可用性的限制。